These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 37351760

  • 1. Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?
    Araujo-Castro M, Hanzu FA, Pascual-Corrales E, García Cano AM, Marchan M, Escobar-Morreale HF, Valderrabano P, Casals G.
    Endocrine; 2023 Oct; 82(1):161-170. PubMed ID: 37351760
    [Abstract] [Full Text] [Related]

  • 2. Characterisation of the urinary steroid profile of patients with nonfunctioning adrenal incidentalomas: A matched controlled cross-sectional study.
    Araujo-Castro M, Casals G, Hanzu FA, Pascual-Corrales E, García Cano AM, Lanza VF, Luis Del Rey Mejías Á, Marchan M, Escobar-Morreale HF, Valderrabano P.
    Clin Endocrinol (Oxf); 2023 Feb; 98(2):165-176. PubMed ID: 35973974
    [Abstract] [Full Text] [Related]

  • 3. Nonfunctioning adrenal incidentalomas with cortisol post-dexamethasone suppression test >0.9 µg/dL have a higher prevalence of cardiovascular disease than those with values ≤0.9 µg/dL.
    Araujo-Castro M, Parra Ramírez P, Martín Rojas-Marcos P, García Centeno R, Gracia Gimeno P, Tomé Fernández-Ladreda M, Sampedro Núñez MA, Higueruela C, Robles Lázaro C.
    Endocrine; 2023 Feb; 79(2):384-391. PubMed ID: 36261701
    [Abstract] [Full Text] [Related]

  • 4. Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas.
    Araujo-Castro M, Parra Ramírez P, Robles Lázaro C, García Centeno R, Gracia Gimeno P, Fernández-Ladreda MT, Sampedro Núñez MA, Marazuela M, Escobar-Morreale HF, Valderrabano P.
    Hormones (Athens); 2021 Dec; 20(4):735-744. PubMed ID: 34273083
    [Abstract] [Full Text] [Related]

  • 5. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?
    Araujo-Castro M, Robles Lázaro C, Parra Ramírez P, Cuesta Hernández M, Sampedro Núñez MA, Marazuela M.
    Endocrine; 2019 Dec; 66(3):650-659. PubMed ID: 31473918
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of Body Composition in Patients With and Without Adrenal Tumors and Without Overt Hypersecretory Syndromes.
    Araujo-Castro M, Pascual-Corrales E, García Cano AM, Marchan M, Casals G, Hanzu FA, Gomez-Bermejo MÁ, Escobar Morreale HF, Valderrabano P.
    Endocr Pract; 2023 Feb; 29(2):110-118. PubMed ID: 36455692
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic accuracy of the different hormonal tests used for the diagnosis of autonomous cortisol secretion.
    Araujo-Castro M, García Cano A, Jiménez Mendiguchía L, Escobar-Morreale HF, Valderrábano P.
    Sci Rep; 2021 Oct 15; 11(1):20539. PubMed ID: 34654835
    [Abstract] [Full Text] [Related]

  • 8. Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas.
    Araujo-Castro M, García Cano AM, Escobar-Morreale HF, Valderrabano P.
    Hormones (Athens); 2023 Mar 15; 22(1):51-59. PubMed ID: 36279032
    [Abstract] [Full Text] [Related]

  • 9. The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk.
    Di Dalmazi G, Fanelli F, Zavatta G, Ricci Bitti S, Mezzullo M, Repaci A, Pelusi C, Gambineri A, Altieri P, Mosconi C, Balacchi C, Golfieri R, Cosentino ER, Borghi C, Vicennati V, Pasquali R, Pagotto U.
    J Clin Endocrinol Metab; 2019 Nov 01; 104(11):5519-5528. PubMed ID: 31381072
    [Abstract] [Full Text] [Related]

  • 10. Performance of DHEAS as a Screening Test for Autonomous Cortisol Secretion in Adrenal Incidentalomas: A Prospective Study.
    Liu MS, Lou Y, Chen H, Wang YJ, Zhang ZW, Li P, Zhu DL.
    J Clin Endocrinol Metab; 2022 Apr 19; 107(5):e1789-e1796. PubMed ID: 35137142
    [Abstract] [Full Text] [Related]

  • 11. Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas.
    Araujo-Castro M, Robles Lázaro C, Parra Ramírez P, García Centeno R, Gracia Gimeno P, Fernández-Ladreda MT, Sampedro Núñez MA, Marazuela M, Escobar-Morreale HF, Valderrabano P.
    J Endocrinol Invest; 2021 Nov 19; 44(11):2349-2357. PubMed ID: 33683661
    [Abstract] [Full Text] [Related]

  • 12. Limited Role of Hair Cortisol and Cortisone Measurement for Detecting Cortisol Autonomy in Patients With Adrenal Incidentalomas.
    Puglisi S, Leporati M, Amante E, Parisi A, Pia AR, Berchialla P, Terzolo M, Vincenti M, Reimondo G.
    Front Endocrinol (Lausanne); 2022 Nov 19; 13():833514. PubMed ID: 35222288
    [Abstract] [Full Text] [Related]

  • 13. Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas.
    Tsagarakis S, Roboti C, Kokkoris P, Vasiliou V, Alevizaki C, Thalassinos N.
    Clin Endocrinol (Oxf); 1998 Aug 19; 49(2):165-71. PubMed ID: 9828902
    [Abstract] [Full Text] [Related]

  • 14. Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test.
    Ueland GÅ, Methlie P, Kellmann R, Bjørgaas M, Åsvold BO, Thorstensen K, Kelp O, Thordarson HB, Mellgren G, Løvås K, Husebye ES.
    Eur J Endocrinol; 2017 Jun 19; 176(6):705-713. PubMed ID: 28298353
    [Abstract] [Full Text] [Related]

  • 15. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
    Tsilchorozidou T, Honour JW, Conway GS.
    J Clin Endocrinol Metab; 2003 Dec 19; 88(12):5907-13. PubMed ID: 14671189
    [Abstract] [Full Text] [Related]

  • 16. Prevalence and incidence of type 2 diabetes mellitus in patients with adrenal incidentalomas: a study of 709 cases.
    Brox-Torrecilla N, García Cano AM, Valderrábano P, Quintero Tobar A, Escobar-Morreale HF, Araujo-Castro M.
    Endocrine; 2023 Sep 19; 81(3):484-491. PubMed ID: 37212980
    [Abstract] [Full Text] [Related]

  • 17. Adrenalectomy improves blood pressure control in nonfunctioning adrenal incidentalomas and glycemic and lipid control in patients with autonomous cortisol secretion.
    Araujo-Castro M, Mínguez Ojeda C, Sánchez Ramírez MN, Gómez Dos Santos V, Pascual-Corrrales E, Fernández-Argüeso M.
    Endocrine; 2022 Oct 19; 78(1):142-150. PubMed ID: 35751779
    [Abstract] [Full Text] [Related]

  • 18. Low DHEAS: A Sensitive and Specific Test for the Detection of Subclinical Hypercortisolism in Adrenal Incidentalomas.
    Dennedy MC, Annamalai AK, Prankerd-Smith O, Freeman N, Vengopal K, Graggaber J, Koulouri O, Powlson AS, Shaw A, Halsall DJ, Gurnell M.
    J Clin Endocrinol Metab; 2017 Mar 01; 102(3):786-792. PubMed ID: 27797672
    [Abstract] [Full Text] [Related]

  • 19. Adrenal steroid metabolites and bone status in patients with adrenal incidentalomas and hypercortisolism.
    Nakao H, Yokomoto-Umakoshi M, Nakatani K, Umakoshi H, Ogata M, Fukumoto T, Kaneko H, Iwahashi N, Fujita M, Ogasawara T, Matsuda Y, Sakamoto R, Izumi Y, Bamba T, Ogawa Y.
    EBioMedicine; 2023 Sep 01; 95():104733. PubMed ID: 37543511
    [Abstract] [Full Text] [Related]

  • 20. Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study.
    Falcetta P, Orsolini F, Benelli E, Agretti P, Vitti P, Di Cosmo C, Tonacchera M.
    Endocrine; 2021 Jan 01; 71(1):178-188. PubMed ID: 32915435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.